Compare LOCO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | TRDA |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 404.4M |
| IPO Year | 2014 | 2021 |
| Metric | LOCO | TRDA |
|---|---|---|
| Price | $10.67 | $11.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $14.50 | ★ $20.00 |
| AVG Volume (30 Days) | 181.1K | ★ 200.0K |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | $61,520,000.00 |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $1.64 | $3.14 |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.29 | $4.93 |
| 52 Week High | $12.65 | $14.27 |
| Indicator | LOCO | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 60.33 |
| Support Level | $10.83 | $10.34 |
| Resistance Level | $11.24 | $12.18 |
| Average True Range (ATR) | 0.32 | 0.75 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 29.02 | 72.98 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.